Tiroid Kanserleri Patolojisinde Yeni Sınıflamalar, Terminoloji ve Günlük Pratiğe Yansımaları

WHO Classification of Tumours Editorial Board, editor. Endocrine and Neuroendocrine Tumours [Internet]. 5th ed. Lyon: International Agency for Research on Cancer; 2025. Available from: https://tumourclassification.iarc.who.int/chapters/36.

Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms [Internet]. Vol. 33, Endocrine Pathology. Springer US; 2022. 27–63 p. Available from: https://doi.org/10.1007/s12022-022-09707-3

Christofer Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30(2).

Baloch Z, LiVolsi VA. Fifty years of thyroid pathology: concepts and developments. Hum Pathol [Internet]. 2020;95(2020):46–54. Available from: https://doi.org/10.1016/j.humpath.2019.09.008

Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol. 2012;19(6):363–73.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–9.

Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nosé V, Mete O. Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol [Internet]. 2021;32(3):327–35. Available from: https://doi.org/10.1007/s12022-021-09683-0

Wasserman JD, Sabbaghian N, Fahiminiya S, Chami R, Mete O, Acker M, et al. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2018;103(5):2009–15.

Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes [Internet]. Vol. 33, Endocrine Pathology. Springer US; 2022. 197–227 p. Available from: https://doi.org/10.1007/s12022-022-09705-5

Nikiforova MN, Nikitski A V., Panebianco F, Kaya C, Yip L, Williams M, et al. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid. 2019;29(2):161–73.

Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: A clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286–95.

Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid. 2020;30(10):1505–17.

Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA, et al. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. J Clin Oncol. 2022;40(1):96–103.

Chambers M, Nosé V, Sadow PM, Tafe LJ, Kerr DA. Salivary-Like Tumors of the Thyroid: A Comprehensive Review of Three Rare Carcinomas. Head Neck Pathol [Internet]. 2021;15(1):212–24. Available from: https://doi.org/10.1007/s12105-020-01193-5

Baloch ZW, Solomon AC, LiVolsi VA. Primary mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: A report of nine cases. Mod Pathol [Internet]. 2000;13(7):802–7. Available from: http://dx.doi.org/10.1038/modpathol.3880140

Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell. 2014;159(3):676–90.

Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, et al. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres. Clin Oncol. 2023;35(1):e60–6.

Højer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. Int J Mol Sci. 2023;24(3).

WHO Classification of Tumours Editorial Board, editor. Endocrine and Neuroendocrine Tumours [Internet]. 5th ed. Lyon: International Agency for Research on Cancer; 2025. Available from: https://tumourclassification.iarc.who.int/chapters/36.

Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms [Internet]. Vol. 33, Endocrine Pathology. Springer US; 2022. 27–63 p. Available from: https://doi.org/10.1007/s12022-022-09707-3

Christofer Juhlin C, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023;30(2).

Baloch Z, LiVolsi VA. Fifty years of thyroid pathology: concepts and developments. Hum Pathol [Internet]. 2020;95(2020):46–54. Available from: https://doi.org/10.1016/j.humpath.2019.09.008

Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol. 2012;19(6):363–73.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–9.

Boyraz B, Sadow PM, Asa SL, Dias-Santagata D, Nosé V, Mete O. Cribriform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. Endocr Pathol [Internet]. 2021;32(3):327–35. Available from: https://doi.org/10.1007/s12022-021-09683-0

Wasserman JD, Sabbaghian N, Fahiminiya S, Chami R, Mete O, Acker M, et al. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2018;103(5):2009–15.

Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes [Internet]. Vol. 33, Endocrine Pathology. Springer US; 2022. 197–227 p. Available from: https://doi.org/10.1007/s12022-022-09705-5

Nikiforova MN, Nikitski A V., Panebianco F, Kaya C, Yip L, Williams M, et al. GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid. 2019;29(2):161–73.

Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: A clinicopathologic study of 58 patients. Cancer. 2006;106(6):1286–95.

Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid. 2020;30(10):1505–17.

Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA, et al. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. J Clin Oncol. 2022;40(1):96–103.

Chambers M, Nosé V, Sadow PM, Tafe LJ, Kerr DA. Salivary-Like Tumors of the Thyroid: A Comprehensive Review of Three Rare Carcinomas. Head Neck Pathol [Internet]. 2021;15(1):212–24. Available from: https://doi.org/10.1007/s12105-020-01193-5

Baloch ZW, Solomon AC, LiVolsi VA. Primary mucoepidermoid carcinoma and sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: A report of nine cases. Mod Pathol [Internet]. 2000;13(7):802–7. Available from: http://dx.doi.org/10.1038/modpathol.3880140

Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell. 2014;159(3):676–90.

Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, et al. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres. Clin Oncol. 2023;35(1):e60–6.

Højer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. Int J Mol Sci. 2023;24(3).